



GLAND PHARMA LIMITED

January 18, 2025

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Conclusion of US FDA Inspection at Pashamylaram Facility, Hyderabad

Ref: Announcement made by the Company dated August 02, 2024

In continuation to our intimation dated August 02, 2024; this is to inform you that following the Inspection for Good Manufacturing Practices (GMP) by US FDA at the Company's Pashamylaram Facility at Hyderabad between 25th July, 2024 and 02nd August, 2024; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.

Request to take the above information on record.

Yours truly,

For Gland Pharma Limited

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer